RecruitingPhase 1NCT06006273

A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors

Sponsor

M.D. Anderson Cancer Center

Enrollment

48 participants

Start Date

Aug 16, 2023

Study Type

INTERVENTIONAL

Conditions

Refractory Solid Tumors

Summary

To find the recommended dose of eribulin that can be given in combination with irinotecan and temozolomide to treat relapsed and/or refractory solid tumors.

Eligibility

Min Age: 1 YearMax Age: 25 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Eribulin, a drug called Irinotecan, and others for people with refractory solid tumors. The study is currently recruiting participants at 1 location. People eligible for this study include aged 1 Year to 25 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGEribulin

Given by vein (IV)

DRUGIrinotecan

Given by vein (IV)

DRUGTemozolomide

Given by PO

Locations(1)

M D Anderson Cancer Center

Houston, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06006273

Related Trials

PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

NCT067216897 locations

Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors

NCT037398273 locations